Figure 3From: Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation Diagnosis of an EML4-ALK-positive non-small cell lung cancer. (A) Immunostaining for ALK protein expression in tumor cells. (B) The results of a break-apart FISH assay of tumor cells from a patient with rearrangement of the gene encoding ALK. Back to article page